finanzen.net

Achieve Life Sciences nach Reverse Split

Seite 25 von 28
neuester Beitrag: 14.10.19 18:43
eröffnet am: 25.05.18 17:22 von: bozkurt7 Anzahl Beiträge: 679
neuester Beitrag: 14.10.19 18:43 von: aktiengirl Leser gesamt: 71824
davon Heute: 51
bewertet mit 3 Sternen

Seite: 1 | ... | 22 | 23 | 24 |
| 26 | 27 | 28  

07.05.19 15:41
1

108 Postings, 844 Tage Dagobert_0815Quartalsbericht am 15. Mai

Für das 1. Quartal 2019 gibt es am 15.Mai einen m.E. sehr positiven Bericht.
D.h. Achieve wird bis dahin noch einen Satz nach oben machen.
Diese Aktie macht doch in diesem Jahr richtig Spaß, auch zukünftig erwarte ich hier noch einiges.
Wie immer m.M.  

13.05.19 16:09

108 Postings, 844 Tage Dagobert_0815...unser Freund aus den USA

bringt zur Zeit alle Kurse gen Süden....  

15.05.19 20:57

660 Postings, 1037 Tage DölauerQuartalsbericht

schon bekannt?  

15.05.19 21:48

108 Postings, 844 Tage Dagobert_0815..erst 4:30 pm eastern time,

noch knapp 45 Minuten dann gibt es den Bericht via webcast  

15.05.19 22:15

130 Postings, 661 Tage Siggi JacksonWird wohl bald ne ke kommen

Nur noch 9,7 Mille Stand 31.3  

15.05.19 22:32

4149 Postings, 5326 Tage martin30smZahlen

Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update

   AddThis Sharing Buttons
   Share to Facebook

Share to TwitterShare to LinkedInShare to Pinterest

SEATTLE and VANCOUVER, British Columbia, May 15, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced first quarter 2019 financial results.

ORCA-1 Trial Status
Achieve's 254-subject Phase 2b ORCA-1 trial of cytisinicline in U.S. smokers completed enrollment in February. The Company announced recently that the last study visit for the last subject enrolled in the ORCA-1 trial has occurred. The trial is evaluating cytisinicline in both the 1.5 mg and 3.0 mg doses on a declining titration schedule as well as three times daily dosing, both over 25 days. The primary efficacy endpoint is reduction in the number of cigarettes smoked during treatment with secondary analyses to be conducted on smoking cessation rates, safety, and compliance. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter.

Maximum Tolerated Dose (MTD) Trial Extension
Achieve recently initiated a trial to assess the MTD for a single administered oral dose of cytisinicline in smokers. The starting dosage of cytisinicline was 6 mg and is increased in separate groups of subjects for each escalated dose level until stopping criteria, based on the occurrence of dose-limiting adverse events, are reached. To date, 21 mg cytisinicline has been evaluated without evidence of dose limiting toxicity. The trial's Data Safety Monitoring Committee has recommended a protocol amendment to evaluate additional higher doses of cytisinicline.

Rick Stewart, Chairman and Chief Executive Officer of Achieve Life Sciences commented, "With the results of the ORCA-1 trial expected by the end of the second quarter, we are rapidly approaching another critical milestone for the cytisinicline development program. Importantly, as confirmed by the tolerability of high dose levels in our MTD study, we believe cytisinicline may offer a differentiated and new treatment option for the millions of people who are battling nicotine addiction."

Financial Results
As of March 31, 2019, the company's cash, cash equivalents, short-term investments and restricted cash were $9.7 million. Each of total operating expenses and net loss for the first quarter of 2019 were $5.9 million.

As of May 15, 2019 Achieve had 6,865,950 shares outstanding.

Conference Call Details
Achieve will host a conference call at 4:30 p.m. Eastern time today, Wednesday, May 15, 2019. To access the webcast, log on to the investor relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, access to the live conference call is available by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 6973659. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the planned cytisinicline clinical development activities, the timing of clinical development activities related to cytisinicline, expectations from current data, expectations regarding when trial data may be reported, the potential market size for cytisinicline and the potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.

Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4

"ORCA is a trademark of Achieve Life Sciences, Inc."

1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 , 179 - 182.e1

Consolidated Statements of Loss

(In thousands, except per share and share data)


                    
                     
                     
                     
                     
           
§
                    
                     
                     
                     
                     
           
§
                    
                     
                     
           
§
 

15.05.19 22:53

57 Postings, 496 Tage Neonblack667OK, und das heisst...

Noch könnte ich bei L&S verkaufen :D  

15.05.19 23:16
0.25$ unter den Erwartungen und gerade als ich noch für 3.78? verkaufen wollte, fällt der Kurs...

Mal gespannt wie es weiter geht.  

16.05.19 15:22

660 Postings, 1037 Tage DölauerEröffnungskurs heute in den USA

Na wer stellt eine Prognose?
Auch zum Schlusskurs!  

16.05.19 15:26
1

4149 Postings, 5326 Tage martin30smMein Tipp für heute:

Eröffnung bei ca. 4 Dollar, dann kurz runter bis 3,70 Dollar... SK bei ca. 4,40 Dollar  

16.05.19 15:32

4149 Postings, 5326 Tage martin30sm@Dölauer: Wie lautet dein Tipp?

16.05.19 15:50
1

660 Postings, 1037 Tage DölauerTipp

Schwer zu sagen, ich denke der Kurs bleibt über 4 Dollar bei wenigen Umsätzen und wird erst steigen, wenn Ende des zweiten Quartals die angekündigten News kommen.    

21.05.19 10:46

108 Postings, 844 Tage Dagobert_0815interessanter Bericht

https://www.aktiencheck.de/news/...e_Sciences_Nicht_vergessen-9911563
Ich werde die günstige Gelegenheit nutzen und unter 3 ? nachkaufen  

28.05.19 16:50
1

108 Postings, 844 Tage Dagobert_0815Weiterer Investor

Adamas Health Care Fund mit 5,37 %  

29.05.19 16:25

108 Postings, 844 Tage Dagobert_0815Hier ist noch viel Power drin...

DAX stürzt ab, Achieve macht weiterhin viel Freude.
Wer hier long bleibt wird belohnt.
Wie immer m.M.  

11.06.19 13:36

4707 Postings, 1665 Tage bozkurt7das ist heftig, was da gerade bei Tradegate

abgeht ... -23 % ?  

11.06.19 15:03

4149 Postings, 5326 Tage martin30smNews

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
3.0 mg, 3 times daily selected as dose for future clinical development

SEATTLE and VANCOUVER, British Columbia, June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced positive results from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. The outcome of the 254-subject, ORCA-1 trial is the selection of 3.0 mg, three times daily (TID) for Phase 3 development.

The primary endpoint was the reduction in daily smoking, a self-reported measure. Three of the four cytisinicline treatment arms demonstrated a statistically significant improvement, as defined in the protocol as p < 0.05, compared to placebo. The fourth arm trended to significance (p= 0.052). Across all treatment arms, over the 25-day treatment period, subjects on cytisinicline experienced a 74-80% median reduction in the number of cigarettes smoked, compared to a 62% reduction in the placebo arms.

The secondary endpoint of the trial was a 4-week continuous abstinence rate, which is the relevant endpoint for regulatory approval. Cytisinicline treatment showed significant improvements in abstinence rates compared to placebo. The most impressive results were observed in the 3 mg TID treatment arm which demonstrated a 54% abstinence rate at week 4, compared to 16% for placebo (p < 0.0001) and a continuous abstinence rate, weeks 5 through 8, of 30% for cytisinicline compared to 8% for placebo (p= 0.005).

All four cytisinicline arms demonstrated statistically significant (p < 0.05) reductions in expired carbon monoxide (CO), a biochemical measure of smoking activity. Expired CO levels declined by a median of 71-80% in the cytisinicline treatment arms, compared to only 38% in the placebo arms. The lack of consistency in the reduction of expired CO levels compared to the self-reported data suggest potential under-reporting of cigarettes smoked by subjects on placebo.

"The robust efficacy results in the simplified, three times daily dosing arms exceeded our expectations, particularly, the statistically significant abstinence rates. This is of importance given that a continuous abstinence rate is the endpoint for regulatory approval in smoking cessation trials," said Rick Stewart, Chairman and CEO of Achieve. "In addition to efficacy, the cytisinicline safety data observed in ORCA-1 reflects the historically strong safety profile already experienced in Central and Eastern Europe."

Adherence to study treatment was greater than 98.5% across all arms and cytisinicline was well-tolerated with no serious adverse events reported. The most commonly reported (>5%) adverse events (AEs) across all cytisinicline treatment arms versus placebo were abnormal dreams, insomnia, upper respiratory tract infections, and nausea. In the 3 mg TID treatment arm versus placebo, the most common AEs were abnormal dreams, insomnia, and constipation (each 6% vs 2%), upper respiratory tract infections (6% vs 14%), and nausea (6% vs 10%).

The Company expects to conduct further analyses of the ORCA-1 trial and submit data for presentation at a future medical meeting. Additionally, Achieve plans to discuss the trial's outcome with the FDA and finalize Phase 3 protocol details in the second-half of 2019.

Achieve would like to thank the investigators, healthcare providers, and subjects whose commitment and efforts to ORCA-1 made this trial a success. Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.

Conference Call Details
Achieve will host a conference call at 8:30 a.m. Eastern time today, Tuesday, June 11, 2019. To access the webcast, log on to the investor relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, access to the live conference call is available by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 6986745. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

About Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

About ORCA-1
ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the safety and effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. The study was designed to evaluate the declining titration schedule, currently utilized in Central and Eastern Europe, compared to a simplified TID schedule at both the 1.5 mg and 3 mg cytisinicline doses compared to placebo. Subjects were provided face-to-face behavioral support over the full course of the study. Smoking abstinence was measured at week 4 (end-of-treatment). Continuous abstinence was also measured at weeks 5 through 8 (end-of-study). Abstinence assessments were verified by expired carbon monoxide (CO), a biochemical measure of smoking activity.

The study was blinded to dosing. Demographics were similar between schedules and for treatment arms in gender, age, years of prior smoking, and number of previous quit attempts. At baseline, subjects in the study reported smoking a median of 20 cigarettes per day. ORCA-1 was initiated in October 2018 and enrolled 254 smokers at eight centers across the United States.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the planned cytisinicline clinical development activities, the timing of clinical development activities related to cytisinicline, the potential market size for cytisinicline and the potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4

"ORCA is a trademark of Achieve Life Sciences, Inc."

1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 , 179 - 182.e1

SOURCE Achieve Life Sciences, Inc.  

11.06.19 15:13

1170 Postings, 3392 Tage AdvamillionärKann das mal kurz einer erläutern?

Der Kurseinbruch ist schon ziemlich heftig heute....

Gruß vom
Advamillionär  

11.06.19 15:34
1

4707 Postings, 1665 Tage bozkurt7es sieht doch eigentlich ganz gut aus:

Der primäre Endpunkt war die Reduzierung des täglichen Rauchens, eine selbst berichtete Maßnahme. Drei der vier Cytisiniclin-Behandlungsarme zeigten eine statistisch signifikante Verbesserung, wie im Protokoll als p <0,05 definiert, im Vergleich zu Placebo. Der vierte Arm tendierte zur Signifikanz (p = 0,052). Über den 25-tägigen Behandlungszeitraum hinweg wurde bei Patienten unter Cytisiniclin in allen Behandlungsarmen eine mediane Reduktion der Anzahl der gerauchten Zigaretten um 74 bis 80% festgestellt, verglichen mit einer Reduktion der Placebo-Arme um 62%.

Der sekundäre Endpunkt der Studie war eine 4-wöchige kontinuierliche Abstinenzrate, die der relevante Endpunkt für die behördliche Zulassung ist. Die Behandlung mit Cytisiniclin zeigte eine signifikante Verbesserung der Abstinenzraten im Vergleich zu Placebo. Die eindrucksvollsten Ergebnisse wurden im 3-mg-TID-Behandlungsarm beobachtet, der in Woche 4 eine Abstinenzrate von 54% aufwies, verglichen mit 16% für Placebo (p <0,0001) und einer kontinuierlichen Abstinenzrate in den Wochen 5 bis 8 von 30% für Cytisiniclin im Vergleich zu 8% für Placebo (p = 0,005).  

11.06.19 15:44

1170 Postings, 3392 Tage AdvamillionärExtreme Kursschwankungen aktuell....

....da sind wohl einige Zocker am Werk...

Gruß vom
Advamillionär  

12.06.19 22:46

16676 Postings, 3477 Tage Balu4uNicht nur hier....

20.06.19 16:22

108 Postings, 844 Tage Dagobert_0815Kurs wird sich erholen

Kurs wurde massiv durch Gewinnmitnahmen eines Investors gedrückt, ist daher ein Einmaleffekt.
Habe heute noch ein paar Aktien für knapp 2,24 ? nachgekauft, m.E. lohnenswert, da es sich hier definitiv weiterhin um ein Superprodukt handelt.
Kann m.E. nur nach Norden gehen.  

20.06.19 16:50

204 Postings, 2714 Tage oroaskanInvestoren

gibts hier  nicht - nur Zocker! Es wird nur heiße Luft geblasen, Leute werden abgezockt und für dumm verkauft!  

Seite: 1 | ... | 22 | 23 | 24 |
| 26 | 27 | 28  
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Daimler AG710000
Deutsche Bank AG514000
NEL ASAA0B733
Apple Inc.865985
Microsoft Corp.870747
Amazon906866
CommerzbankCBK100
Aurora Cannabis IncA12GS7
BASFBASF11
Volkswagen (VW) AG Vz.766403
Infineon AG623100
TUITUAG00
BayerBAY001
TeslaA1CX3T